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x Proteomics highlights potential conserved mechanisms of pathogenesis in SMA 
x  GAP43, GAPDH, UBA1 and NCAM are decreased in three separate proteomic 
studies of SMA 
x LMNA, ANXA2 and COL6A3 are increased in three separate proteomic studies of 
SMA 
x Manipulation of these proteins may modulate the severity of disease in SMA  
 
Abstract 
The neuromuscular disease spinal muscular atrophy (SMA) is a leading genetic cause of 
infant mortality, resulting from low levels of full-length survival motor neuron (SMN) 
protein. Despite having a good understanding of the underlying genetics of SMA, the 
molecular pathways downstream of SMN that regulate disease pathogenesis remain unclear. 
The identification of molecular perturbations downstream of SMN is required in order to 
fully understand the fundamental biological role(s) for SMN in cells and tissues of the body, 
as well as to develop a range of therapeutic targets for developing novel treatments for SMA.  
Recent developments in proteomic screening technologies have facilitated proteome-wide 
investigations of a range of SMA models and tissues, generating novel insights into disease 
mechanisms by highlighting conserved changes in a range of molecular pathways. 
Comparative analysis of distinct proteomic datasets reveals conserved changes in pathways 
converging on GAP43, GAPDH, NCAM, UBA1, LMNA, ANXA2 and COL6A3. Proteomic 
studies therefore represent a leading tool with which to dissect the molecular mechanisms of 
disease pathogenesis in SMA, serving to identify potentially attractive targets for the 
development of novel therapies. 
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Spinal Muscular atrophy (SMA) is an autosomal recessive disease, primarily characterised by 
loss of motor neurons from the anterior horn of spinal cord and atrophy of skeletal 
musculature. The disease is considered to represent a “continuum of clinical severity” [1], but 
is broadly subdivided into four sub-types, depending on the developmental milestones that 
are reached: type 1 (severe), type 2 (intermediate), type 3 (mild) and type 4 (adult-onset) [1]. 
Type 1 SMA is the leading genetic cause of infantile death in the western world and infants 
typically die before the age of two due to respiratory failure [2,3].  
 
The cause of SMA for the majority (>95%) of patients is a loss-of-function defect in the 
SMN1 gene, resulting in reduced levels of the ubiquitously-expressed survival of motor 
neuron (SMN) protein [4]. Although most humans possess at least one copy of an additional - 
and almost identical - SMN2 gene, protein translated from SMN2 is much less stable and 
unable to fully compensate for loss of SMN1 [4-6]. The severity of the disease is largely 
dependent upon the number of SMN2 copies that are present. Thus, patients with the most 
severe phenotypes tend to have a lower copy number of SMN2 [7].  
 
At present, there are no disease modifying treatments available for SMA, and palliative 
support is the best that can be offered to patients. However, significant progress has been 
made over the last two decades in terms of both basic research and pre-clinical development, 
leading to the identification of several promising therapeutic approaches entering clinical 
trials. Almost all of this therapeutic work has focused on identifying compounds aimed at 
targeting either SMN2 promoter activation, modulation of splicing, or SMN1 replacement 
gene therapy [8]. In contrast, the ability to identify potential non SMN-focused therapeutic 
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targets has been hampered by a lack of understanding of the core molecular pathways acting 
downstream from SMN to modulate disease pathogenesis in SMA [9]. 
 
SMN is a ubiquitously expressed protein with a role in the assembly of small nuclear 
ribonucleic proteins (snRNPs) in the cytoplasm and subsequent transport into the nucleus for 
RNA splicing [4,10]. To do this, SMN functions as a core complex with at least eight other 
proteins: gemins 2-8 and unrip. In addition to this well-characterised housekeeping role, 
SMN appears to interact with several other proteins required for the transport and correct 
localisation of mRNAs in axons [11-13]. Whilst some of these SMN interactions are 
relatively stable (in the case of the core complex with gemin proteins), there are many other 
interactions that are expected to be more transient [14]. A search of two protein interaction 
databases, Biomolecular Interaction Network Database (BIND) and the Molecular 
INTeraction database (MINT), suggests that in excess of 100 proteins have the potential to 
interact with SMN. Given the potential size of the “SMN interactome” (Figure 1), and the 
fact that each of those interacting proteins may also have their own unique “interactome”, it 
seems highly probable that a reduction of SMN should have significant downstream 
molecular consequences affecting a range of different target proteins and pathways.  
 
Recent advances in proteomic technologies have enabled researchers to take an unbiased, 
global view of the proteome, and to conduct quantitative comparisons and characterisations 
of disease-relevant tissues and model systems relevant to a broad range of conditions 
affecting human health. Such technologies therefore provide un-paralleled opportunities to 
accurately monitor and quantify downstream molecular consequences of SMN depletion in 
vivo and in vitro. It is therefore not surprising that proteomics approaches have been 
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employed by a variety of research groups investigating mechanisms of disease pathogenesis 
in SMA.   
 
Despite the wealth of information that proteomic investigations can generate, two main 
challenges have hampered effective translation of findings from studies using these 
approaches to investigate mechanisms of disease pathogenesis in SMA. The first challenge is 
that different proteomics-based studies of SMA have utilised a variety of model systems and 
tissue sampling techniques. This has the potential to result in unavoidable, model/tissue-
specific identified perturbations into proteomic data that are difficult to isolate from core 
molecular disease pathways. The second challenge is that proteomics studies typically yield 
extensive lists of proteins exhibiting differential expression profiles based on an incomplete 
coverage of the entire proteome, with a select few candidates from each study often given 
special attention for further verification and validation.  The selection of such candidate 
proteins for further study is often subjective and will always result in other potentially 
important proteins and pathways being overlooked. As a result, there are now a number of 
large proteomic datasets from several research groups that contain crucial, but likely 
overlooked, information regarding the core molecular regulators of disease pathogenesis in 
SMA. Despite these challenges, the availability of such a broad range of SMA proteomic 
datasets presents the opportunity to generate significant new insights into mechanisms of 
disease pathogenesis by interrogating raw datasets to identify common molecular changes. 
The identification of conserved alterations downstream of SMN perturbations, independent of 
the experimental model and technical approach used, would therefore serve to highlight 
“core” molecular responses to low levels of SMN. Such “core” responses would likely 
represent attractive SMN-independent targets for the development of novel therapies for 
SMA.  




SMA studies employing proteomic screens: An overview  
Nine publications to date have used unbiased proteomic comparisons for the identification of 
differentially-expressed proteins in SMA (Table 1). These studies are considered unbiased 
because they did not depend on the use of capture or array technology for enrichment of 
differentially expressed proteins. Instead, the entire proteome was subject to analysis using a 
variety of protein separation and mass spectrometry approaches. As expected, there is a clear 
correlation between the precise methodology used and the number of differentially expressed 
proteins identified in each study; 2D-gel based studies yielded far fewer proteins than more 
recently-developed isobaric (e.g. iTRAQ) or label-free technologies, even when identical 
mass spectrometry instrumentation was used. Despite the relatively small number of studies, 
both in-vivo and in-vitro studies are represented, incorporating experimental assessment of 
both mouse models and SMA patient samples (Table 1). The studies include comparisons 
made of mature cells and tissues [15-21], as well as comparisons of cell types at various 
stages of cellular differentiation, including undifferentiated and differentiated embryonic 
stem cells [22], induced pluripotent stem cell-derived motor neurons [16], and Schwann cells 
[23]. Also noteworthy is that three of the studies [15-17] conducted comparisons using 
material that was not clinically affected by SMA (i.e. plasma and skin fibroblasts), thus 
enabling the possibility of identifying systemic consequences of reduced SMN in the absence 
of overt disease pathology. Taken together, these nine published proteomic studies cover a 
broad range of the most common SMA models, cells and tissues utilised by the research 
community. Comparisons between and across experimental datasets from these studies are 
therefore likely to identify conserved molecular responses to low levels of SMN directly 
relevant to disease pathogenesis. 
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Multi-study proteomic identification of conserved molecular responses to reduced levels 
of SMN in SMA 
Review of the differentially expressed proteins from the studies detailed in Table 1 identified 
29 proteins that showed conserved changes across two or more separate proteomic-based 
studies of SMA (Table 2). Of these 29 proteins, 19 revealed increased expression in response 
to low levels of SMN and 10 revealed decreased expression levels (Table 2). These proteins 
therefore represent a novel potential “molecular fingerprint” of SMA pathogenesis. 
 
Of the 10 proteins that were decreased in expression in SMA cell and tissue samples, four 
were found to be consistently decreased across three separate studies (Table 2), suggesting 
that they may represent a conserved response to lowered levels of SMN and as a result 
warrant significant further experimental attention. One of these proteins, ubiquitin activating 
enzyme 1 (UBA1), has been strongly linked to neurodegenerative pathways across a range of 
diseases, including SMA [24]. Of particular relevance too is that mutations in the human 
UBE1 gene, that encodes UBA1 protein, are associated with a rare X-linked infantile form of 
SMA [25,26]. Despite differences in experimental platforms, species and tissue / cell type 
utilised in the quantitative proteomic studies, the percentage reduction of UBA1 is strikingly 
comparable across all three studies. Aghamaleky et al. [23] detected a 50% decrease of 
UBA1 in SMA mouse Schwann cells compared to control; Wishart et al. [20] detected a 57% 
decrease in SMA mouse hippocampal synaptosomes; Fuller et al. [16] detected a 52% 
decrease in UBA1 in SMA patient iPSC-derived motor neurons.  
 
Further experimental evidence has verified that UBA1 levels are significantly depleted at 
both the gene and protein level in iPS-derived motor neurons from three individual SMA 
patients [16], and at the tissue and cellular level in mouse models of SMA. The reduction in 
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mouse models of SMA contributes, at least in part, to widespread perturbations in ubiquitin 
homeostasis [20,23,27]. Importantly, experimental suppression of UBA1, using both genetic 
and pharmacological approaches, was sufficient to fully phenocopy the SMA motor neuron 
phenotype in zebrafish [20], and pharmacological suppression of UBA1 in normal Schwann 
cells phenocopied the differentiation/myelination defects observed in SMA Schwann cells 
[23]. Thus, the robust finding of depleted levels of UBA1 across multiple proteomic studies 
of SMA suggests that this protein is likely to be a major contributor to disease pathogenesis 
in SMA. 
 
Also reduced across three separate comparisons was the traditional “housekeeping” 
glycolytic enzyme, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Table 2). The 
reduction seen in SMA mouse Schwann cells (56%; [23]) was slightly greater than that seen 
across the isoforms of GAPDH that were detected in the SMA mouse hippocampus 
comparison (approximately 40% reduction on average [18]). It was not possible to compare 
the average percentage reduction seen in SMA patient plasma samples with the other studies 
because proteins were expressed according to their correlation with the Modified 
Hammersmith Functional Motor Scale, rather than relative fold change [15].  
 
Evidence linking GAPDH directly to SMN can also be found from a previous high-
throughput yeast two-hybrid screen [28], although (as with other protein candidates identified 
from similar high-throughput studies) it would appear that this has association has since been 
overlooked. Notably, the observation of reduced levels of GAPDH in SMA is consistent with 
a role as an SMN-interactor, since many other SMN-binding proteins are also dysregulated 
and/or differentially expressed in SMA models [14,20,29,30]. Although it has been widely 
implicated in cellular metabolic processes, GAPDH has also been linked to a range of 
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pathways with particular relevance to the nervous system and neurodegeneration, including 
apoptosis [31], and vesicle and axonal transport [32]. Documented variation in the mRNA 
and protein levels of GAPDH in other neuropathological events have been reported [33], and 
suggest that it may play a key role in neurodegenerative processes. Further investigations into 
the role of GAPDH in SMA pathogenesis therefore appear warranted.  
 
In addition to implications for SMA pathogenesis, the significance of reduced GAPDH in 
SMA models should be viewed as a cautionary note, in so far that its use (as well as that of 
other house keeping proteins such as actin and tubulin) as an internal loading control for gene 
expression and western blot analysis may be unreliable [34]. As such, it may be necessary to 
revisit candidate proteins and genes from studies that have concluded little or no correlation 
with SMA in instances when levels were normalized to GAPDH (or other “house keeping” 
protein) expression. 
 
Two other proteins whose levels were consistently reduced across three separate proteomic 
comparisons were growth-associated protein 43 (GAP43 or neuromodulin) and neural cell 
adhesion molecule (NCAM) (Table 2). Interestingly, both GAP43 and NCAM are known 
binding partners of the multi-functional calcium-binding protein calmodulin [35,36] – which 
itself features in Table 2 as a down-regulated protein detected in two separate proteomic 
comparisons.  
 
GAP43 levels were reduced by approximately 65% in iPS-derived SMA motor neurons [16], 
and by 35% and 22% in the SMA mouse hippocampus [18] and hippocampal synaptosomes 
[20] respectively (Table 2). Similarly, reduced levels of GAP43 have been detected in the 
CSF of human patients affected by a wide range of neurological disorders [37], including 
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motor neuron disease, movement disorders (e.g. Parkinson’s disease) and multiple sclerosis. 
Considered to play a key role in axonal pathfinding, GAP43 is required for survival beyond 
early postnatal development in the mouse [38]. Reports have demonstrated increased levels 
of GAP43 during axonal growth in the rat [39] and during axonal regeneration following 
neurological injury of toad retinal ganglion cells [40] and the goldfish retina [41]. Very 
recently, reduced levels of GAP43 mRNA and protein in axons and growth cones of SMA 
mice were reported [42]. SMN appears to be responsible for regulating the localization and 
translation of GAP43 mRNA in these axons and restoration of GAP43 mRNA and protein 
levels by overexpression of the mRNA binding proteins, HuD and IMP1, rescue axonal 
growth defects in the SMA mice [42]. These studies illustrate that GAP43 is implicated in 
axonal growth / repair pathways and as such, represents a promising neuronal target for SMA 
therapy. 
 
NCAM is a cell-surface protein that has been associated with cell–cell adhesion, neurite 
outgrowth and plasticity, and memory formation [43]. Maintenance of NCAM homeostasis is 
also important for neuronal growth and survival since both increased and decreased levels of 
NCAM have been linked to a wide range of neurological disorders (reviewed by Gnanapavan 
and Giovannonib [44]). For example, while levels of NCAM increase following axonal injury 
[45,46] and atrophic fibers in type I and II SMA muscle biopsies appear to express high levels 
of NCAM [47], NCAM deficient mice display hippocampal dysplasia and loss of septal 
cholinergic neurons [48]. Increased life-span and improved behavioural performance was 
seen in a mouse model of the motor neuron disease amyotrophic lateral sclerosis (ALS), 
following transplantation of human umbilical cord blood cells carrying adeno-viral vectors 
expressing a neuro-protective factor and NCAM [49]. It seems highly pertinent therefore, that 
future studies should aim to determine whether modulating the severity of SMA is also 
Page 11 of 32
12 
 
possible by manipulation of NCAM levels, which until now, have been overlooked in terms 
of their role in SMA pathogenesis. 
 
Of the 10 proteins that revealed increased expression in SMA cell and tissue samples, three 
were consistently changed across three separate proteomic comparisons (Table 2). Collagen 
VI, alpha 3 chain (COL6A3) was increased in SMA patient plasma [15] and in SMA patient 
fibroblasts and iPS-derived motor neurons [16]. Of particular interest is that when SMA 
fibroblasts were quantitatively compared to control fibroblasts, 18 proteins were differentially 
expressed but only one of these, collagen alpha-3 VI, was also differentially expressed in the 
same direction when genetically matched SMA iPS-derived motor neurons were compared to 
control motor neurons.  
 
Over expression of COL6A3 is also seen in various types of cancer [50-52] and mutations in 
this gene can cause Ullrich congenital muscular dystrophy (CMD) and Bethlem myopathy 
[53]; both of which involve muscle and connective tissue problems. Though collagen VI is a 
well-known extracellular matrix protein, little is known about the particular characteristics of 
the COL6A3 isoform, except that it may play a role in advanced stages of neural crest 
development [54]. The relevance of an increase in the levels of COL6A3 in SMA may reflect 
an attempted protective response, since an increase in collagen VI appears to confer neuronal 
protection under cell stress [55].   
 
Published interactors of SMN, annexin A2 (ANXA2) and the intermediate filament protein 
lamin A/C (LMNA) [56], were increased in expression in Schwann cells and muscle from 
SMA mice and in iPS-derived motor neurons from an SMA patient (Table 2). Mutations in 
LMNA cause a range of disorders, including muscular dystrophies such as Charcot-Marie-
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Tooth disease and Emery-Dreifuss muscular dystrophy [57]. Given that mutations in the 
LMNA gene can cause an SMA phenotype [58,59], it is surprising that further studies to 
explore the relationship between LMNA and SMA have not been pursued.   
 
Depletion of SMN in the NSC-34 mouse motor neuron cell line resulted in a 50% increase in 
the levels of ANXA2 mRNA [60] which correlates well with the 57% increase of ANXA2 
protein seen in iPS-derived motor neurons from an SMA patient [16] (Table 2). Over-
expression of ANXA2 by transient transfection induces the disassembly of Cajal bodies and 
relocalization of coilin [61], the “bridge” protein that mediates recruitment of SMN to the 
Cajal body [62]. This is particularly interesting in the current context, and may offer insight 
into the likely downstream consequences of increased ANXA2 in SMA cells, given that 
depletion of SMN also disrupts Cajal body formation and localization of coilin [63,64]. 
 
Refinement of single quantitative proteomics datasets 
In addition to highlighting conserved changes present across several studies, review of multi-
study proteomic comparisons are likely to be useful for refining single proteomics datasets by 
highlighting potential “false positives”. Differentially expressed proteins that one might 
consider as “false positives” could arise due to unavoidable imprecisions in tissue sampling 
techniques, the impact of genetic diversity between the individual samples, the heterogeneous 
nature of some cell cultures, the developmental status of the samples, or differences in 
disease severity and progression. An example of the impact of the latter comes from our own 
previous work where we quantitatively compared the proteome of primary skin fibroblasts 
from an SMA patient with an unaffected SMA carrier. Myogenic cells present in the SMA 
fibroblast cell line but undetectable in the other resulted in an apparent increase in the 
myoblast-specific protein, desmin in the SMA cells [65]. 




Based on a combined review of raw data concerning differentially expressed proteins from 
the studies detailed in Table 1, 37 proteins were identified that appeared to have altered 
expression in one particular SMA cell type or tissue but with opposing detection in another. 
These contradictions are summarised in Table 3. If we were to speculate about these 
contradictions in the context of SMA, it would be parsimonious to suggest that some likely 
reflect a unique response of that particular system / cell type to reduced SMN, and could be 
useful for explaining the known disparity between vulnerabilities of distinct cell and tissue 
types in SMA [3]. However, “… nature seems unaware of our intellectual need for 
convenience and unity, and very often takes delight in complication and diversity” [66], and 
in reality, the complex diversity of changes observed between proteomic data sets may 
simply represent the highly complex biological systems being examined. Such systems are 
not ‘static’ and will represent cells, tissues and organs at different stages of differentiation, 
development, and disease time-course. Thus, the ability to compare data across multiple 
proteomic datasets generated from a range of tissue samples offers the possibility of refining 
the output of a single dataset in order to minimize the influence of such variables. The wealth 
of proteomic data now available in the public domain makes it possible for future studies of 
SMA to undertake such comparative assessments. 
 
Conclusions  
Proteomics techniques offer a powerful tool for obtaining disease-relevant mechanistic 
insights into SMA. By reviewing multiple proteomic datasets, it is possible to identify 
conserved molecular changes downstream of SMN occurring across a range of model 
systems. These changes likely represent “core” regulators of disease pathogenesis and, as 
such, may represent novel therapeutic targets. It will now be important to verify these 
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changes biochemically in a range of cells and tissues throughout disease progression and to 
determine whether their expression levels correlate with clinical severity. Therapeutic 
strategies for pharmacological or genetic manipulation of these molecules - or manipulation 
of upstream regulators of groups of molecules – offers the potential to complement strategies 
directed solely at SMN.  
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Figure 1: The SMN interactome 
Ingenuity Pathway Analysis (IPA) software-based identification of all known interacting 
partners of SMN protein reported in the published literature. Candidate interactors are 
organised based on their predominantly reported subcellular localisation and does not mean 
that they are exclusively restricted to these positions. These interactions are direct (solid 
lines) or indirect (dotted lines), and may have been reported following identification at the 
genomic, transcriptomic or proteomic (DNA,RNA and/or protein) level. As a result, the 
schematic presented here represents the known “interactome” for SMN as identified by IPA. 
 
Table 1: Overview of SMA studies employing proteomic screens 
The nine publications that have used unbiased proteomic comparisons to date for the 
identification of differentially-expressed proteins in SMA.  
*This data resulted from re-analysis of a previously published raw dataset [66].  
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Table 2: The conserved molecular responses to reduced levels of SMN in SMA 
Individual proteins that were differentially expressed across two or more separate comparisons are shown, along with the number of studies they 
were identified in (“repeat hits”), the corresponding SMA model and any additional evidence for a role in the pathophysiology of SMA. 







Additional evidence in the pathophysiology 
of SMA 
Annexin A2 3 
Mouse Schwann cells [23] 
Type I patient motor neurons [16] 
P5 mouse muscle [21] 
x Published interactor of SMN [56]. 
x Depletion of SMN in the NSC-34 mouse 
motor neuron cell line resulted in 
increased levels of ANXA2 mRNA [60]. 
Lamin A/C 3 
Mouse Schwann cells [23] 
Type I patient motor neurons [16] 
P5 mouse muscle [21] 
x Published interactor of SMN [56]. 
x Mutations in the LMNA gene can cause 
an SMA phenotype [58, 59]. 
Collagen alpha 3 (VI) 3 
Type I patient skin fibroblasts [16] 
Type I patient motor neurons [16] 
Type I, II and III patient plasma [15] 
- 
Gelsolin 2 
Mouse Schwann cells [23] 
Type I, II and III patient plasma [15] 
- 
Calreticulin 2 
Type I patient motor neurons [16] 
P5 mouse muscle [21] 
x Increased expression verified by 
western blotting in SMA mouse and 
patient muscles [21] 
Tropomyosin 3 2 
Mouse hippocampus [18] 
Mouse embryonic stem cells (differentiated) [22] 
- 
ATP synthase subunits 2 
Mouse hippocampus synaptosomes [20] 
Mouse Schwann cells [23] 
- 
Actin-related protein 2/3 
complex 
2 
Mouse hippocampus synaptosomes [20] 
Type I patient motor neurons [16] 
- 
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Collagen alpha 1 (VI) 2 
Type I patient skin fibroblasts [16] 
Type I, II and III patient plasma [15] 
- 
Tubulin alpha 2 
Mouse hippocampus synaptosomes [20] 
Mouse embryonic stem cells (differentiated) [22] 
- 
Plectin 2 
Mouse Schwann cells [23] 
P5 mouse muscle [21] 
- 
SOD1 2 
Mouse Schwann cells [23] 
Mouse hippocampus [18] 
x SMN overexpression improves 
neuromuscular function and motor 
neuron survival in SOD1 mice [68] 
Serpin H1 2 
Mouse Schwann cells [23] 
Type I patient motor neurons [16] 
- 
Annexin A5 2 
Mouse embryonic stem cells (differentiated) [22] 
Mouse Schwann cells [23] 
- 
Filamin 2 
Mouse Schwann cells [23] 
Type I patient motor neurons [16] 
- 
Collagen alpha 1 (I) 2 
Mouse Schwann cells [23] 
Type I patient motor neurons [16] 
- 
Collagen alpha 2 (I) 2 
Mouse Schwann cells [23] 
Type I patient motor neurons [16] 
- 
Hypoxia up-regulated protein 1 2 
Mouse Schwann cells [23] 
Type I patient motor neurons [16] 
- 
Glucose-6-phosphate isomerase 2 
Mouse Schwann cells [23] 
P5 mouse muscle [21] 
- 
 






repeat hits  
 
SMA model 
Additional evidence in the pathophysiology 
of SMA 
UBA1 3 
Mouse hippocampus synaptosomes [20] 
Mouse Schwann cells [23] 
Type I patient motor neurons [16] 
x Mutations in the UBE1 gene are 
associated with a rare X-linked infantile 
form of SMA [25,26]. 
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x Experimental suppression of UBA1 
phenocopied the SMA motor neuron 
phenotype in zebrafish [20], and 
phenocopied the Schwann cells defects 
observed in SMA [23]. 
NCAM 3 
Mouse hippocampus [18] 
Type I, II and III patient plasma [15] 
Type I patient motor neurons [16] 
x Atrophic fibers in type I and II SMA 
muscle biopsies express high levels of 
NCAM 
GAP43 (neuromodulin) 3 
Mouse hippocampus [18] 
Mouse hippocampus synaptosomes [20] 
Type I patient  motor neurons [16] 
x Reduced levels of GAP43 mRNA and 
protein in axons and growth cones of 
SMA mice [42].  
x Restoration of GAP43 mRNA and 
protein levels rescued axonal growth 
defects in the SMA mice [42]. 
GAPDH 3 
Mouse Schwann cells [23] 
Mouse hippocampus [18] 
Type I, II and III patient plasma [15] 
x Published interactor of SMN (from 
yeast two-hybrid screen) [28] 
Heat shock protein 90B 2 
Mouse embryonic stem cells (differentiated) [22] 
P5 mouse muscle [21] 
- 
Calmodulin 2 
Mouse hippocampus [18] 
Type I patient skin fibroblasts [16] 
- 
Catalase 2 
Type I, II and III patient plasma [15] 
Type I patient motor neurons [16] 
- 
Peroxiredoxin 2 2 
Mouse Schwann cells [23] 
Type I, II and III patient plasma [15] 
- 
Aldehyde dehydrogenase 2 
Mouse embryonic stem cells (differentiated) [22] 
Mouse Schwann cells [23] 
- 
Alcohol dehydrogenase class 3 2 
Mouse Schwann cells [23] 








Table 3: Proteins with contradictory expression levels in SMA models 
A number of proteins appear to be increased or decreased in expression in a particular SMA cell type or tissue but showed the opposite trend in 
another. (d) = differentiated.  
Proteins with contradictory expression levels in SMA models  
 
Protein name 
Increased in SMA Decreased in SMA 
Aspartate aminotransferase P5 mouse muscle [21] Type I patient motor neurons [16] 
Caldesmon 
Mouse Schwann cells [23] 
Type I patient motor neurons [16] 
Type I patient skin fibroblasts [16] 
Catenin alpha Mouse Schwann cells [23] Type I patient motor neurons [16] 
Catenin beta Mouse hippocampus synaptosomes [20] Type I patient motor neurons [16] 
Endoplasmin Type I patient motor neurons [16] Mouse Schwann cells [23] 
Fructose bisphosphate aldolase 
Mouse Schwann cells [23] 
Mouse hippocampus synaptosomes [20] 
Mouse hippocampus [18] 
Galectin Type I patient motor neurons [16] Mouse (NSC34) cells [19] 
Glyoxylase 1 Mouse embryonic stem cells (d) [22] Type I, II and III patient plasma [15] 
hnRNP K Mouse Schwann cells [23] Mouse (NSC34) cells [19] 
Hspa9/GRP75/Stress-70 protein 
Mouse Schwann cells [23] 
Mouse hippocampus synaptosomes [20] 
P5 mouse muscle [21] 
Mouse embryonic stem cells (d) [22] 
HSP90a 
Mouse hippocampus [18] 
Type I patient motor neurons [16] 
Mouse hippocampus synaptosomes [20] 
Hspd1 Mouse Schwann cells [23] 
Mouse hippocampus [18] 
Mouse hippocampus synaptosomes [20] 
Inorganic pyrophosphatase Mouse hippocampus synaptosomes [20] Type I patient motor neurons [16] 
Comment [A1]: Author: there are two different 
table captions were provided, and this has been 
retained. Please check and confirm it is correct. 
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Macrophage migration inhibitory factor Mouse hippocampus synaptosomes [20] Type I, II and III patient plasma [15] 
MARCKS Mouse hippocampus synaptosomes [20] Mouse hippocampus [18] 
Myosin 3 Type I patient motor neurons [16] Type I patient skin fibroblasts [16] 
Park7 Mouse hippocampus synaptosomes [20] Type I, II and III patient plasma [15] 
Periostin Type I patient motor neurons [16] P5 mouse muscle [21] 
Phosphoglycerate kinase 1 Mouse hippocampus synaptosomes [20] Mouse Schwann cells [23] 
Phosphoglycerate mutase Mouse hippocampus [18] 
Mouse hippocampus synaptosomes [20] 
Mouse Schwann cells [23] 
Profilin 1 Mouse Schwann cells [23] Type I, II and III patient plasma [15] 
Prolyl 4-hydroxylase alpha 2 and alpha 1 Type I patient motor neurons [16] Mouse Schwann cells [23] 
Reticulon Mouse Schwann cells [23] P5 mouse muscle [21] 
Ribosome-binding protein 1 Type I patient motor neurons [16] P5 mouse muscle [21] 
SOD1 
Mouse Schwann cells [23] 
Mouse hippocampus [18] 
Type I, II and III patient plasma [15] 
Sulfated glycoprotein 1 Mouse hippocampus synaptosomes [20] Mouse Schwann cells [23] 
Synaptopodin-2 Type I patient motor neurons [16] Type I patient skin fibroblasts [16] 
S100 A4 Mouse Schwann cells [23] Type I, II and III patient plasma [15] 
T-complex protein 1 
Mouse hippocampus synaptosomes [20] 
Mouse Schwann cells [23] 
P5 mouse muscle [21] 
Mouse hippocampus [18] 
UCHL1 
Mouse embryonic stem cells (d) [22] 
Mouse Schwann cells [23] 
Type I patient skin fibroblasts [17] 
Mouse hippocampus synaptosomes [20] 
Type I patient skin fibroblasts [16] 
 
 
Type I patient motor neurons [16] 
VDAC1 Type I patient skin fibroblasts [16] Mouse Schwann cells [23] 
Vimentin P5 mouse muscle [21] Type I patient motor neurons [16] 
Zyxin Type I patient motor neurons [16] Type I patient skin fibroblasts [16] 
14-3-3 gamma 
Mouse Schwann cells [23] 
Mouse hippocampus synaptosomes [20] 
Mouse embryonic stem cells (d) [22] 
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40S S3 Type I patient motor neurons [16] Mouse Schwann cells [23] 
2',3'-cyclic-nucleotide 3'-phosphodiesterase Type I patient skin fibroblasts [16] Type I patient motor neurons [16] 
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